Abstract
The B-cell activating factor (BAFF) cytokine has important functions for the survival and maturation of B lymphocytes, which implies that this cytokine might play a role in the development of antibody-mediated rejection (AMR) after kidney transplantation. In our study, we compared the concentrations of the soluble BAFF cytokine in kidney graft recipients with AMR and patients without rejection with the goal of testing the hypothesis whether BAFF level measurement might be useful as a diagnostic marker of AMR. The study included a cohort of 19 high-risk patients with diagnosed AMR and 17 control patients free of rejection. BAFF was measured in all patients before transplantation, during the rejection episodes, and three months after transplantation in patients free of rejection using the Luminex technique. Before transplantation, the serum concentrations of BAFF in patients with AMR and kidney recipients without rejection did not significantly differ. After transplantation, however, BAFF levels were significantly lower in patients with AMR and also in patients with concurrent humoral and cellular rejection compared with patients without rejection (p < 0.05 and p < 0.01, respectively). No correlation was found between BAFF and the production of donor-specific antibodies (DSA) before and after transplantation. Patients experiencing AMR and simultaneous cellular and AMR had significantly lower concentrations of BAFF in comparison with patients free of rejection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banham G, Prezzi D, Harford S et al (2013) Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 96:413–420
Bloom D, Chang Z, Pauly K et al (2009) BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 9:1835–1845
Cherukuri A, Salama AD, Carter C et al (2012) An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. Am J Transplant 12:919–931
Colvin RB (2007) Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 18:1046–1056
Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5:807–817
Longshan L, Dongwei L, Qian F et al (2014) Dynamic analysis of B-cell subsets in de novo living related kidney transplantation with induction therapy of basiliximab. Transplant Proc 46:363–367
Mackay F, Ambrose C (2003) The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 14:311–324
Mariette X, Roux S, Zhang J et al (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis 62:168–171
Mukhopadhyay A, Ni J, Zhai Y et al (1999) Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 274:15978–15981
Nardelli B, Belvedere O, Roschke V et al (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97:198–204
Ota M, Duong BH, Torkamani A et al (2010) Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 185:4128–4136
Scapini P, Nardelli B, Nadali G et al (2003) G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 197:297–302
Schneider P, MacKay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756
Snanoudj R, Candon S, Roelen DL et al (2014) Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation. Transplantation 97:917–924
Solez K, Colvin RB, Racusen LC et al (2008) Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753–760
Thibault-Espitia A, Foucher Y, Danger R et al (2012) BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant 12:2754–2762
Xu H, He X, Liu Q et al (2009) Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc 41:1552–1556
Zarkhin V, Kambham N, Li L et al (2008) Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 74:664–673
Zhang J, Roschke V, Baker KP et al (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6–10
Acknowledgements
This study was supported by IKEM Research Project No. 00,023,001 of the Ministry of Health, Czech Republic.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. Slavcev and J. Brozova equally contributed to this publication.
About this article
Cite this article
Slavcev, A., Brozova, J., Slatinska, J. et al. Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft. Arch. Immunol. Ther. Exp. 64 (Suppl 1), 47–53 (2016). https://doi.org/10.1007/s00005-016-0428-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-016-0428-4